SOLVENTUM CORP

Drug pipeline (4)

Asset	Stage	Revenue	Trials	Status
AVAGARD	approved	—	12	approved
DURAPREP	approved	—	1	approved
PERIDEX	approved	—	11	approved
SOLUPREP S	approved	—	11	approved

Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.

Clinical trials (16)

NCT ID	Phase	Status	Start	Completion	Sponsor name	Title
NCT04601103	—	terminated	2020-01-06	2020-03-10	Solventum US LLC	3M Oral Rinse Incidence and Patient Acceptance of Sloughing When Used With Sodium Lauryl Sulfate (SLS) Toothpastes
NCT00731042	phase4	completed	2008-03-01	2008-04-01	Solventum US LLC	A Two-week Crossover Evaluation of Two Hand Antiseptic Products on Skin Condition in Healthy Human Subjects
NCT00516906	phase2_3	completed	2007-10-01	2007-12-01	Solventum US LLC	Clinical Performance of a Chlorhexidine Antimicrobial Dressing
NCT01290978	phase4	completed	2010-02-01	2010-03-01	Solventum US LLC	Compare Effect of Surgical Antiseptic Preparations on Incise Drape Adhesion to Skin
NCT03155204	—	completed	2017-04-25	2018-01-21	Solventum US LLC	Comparison of the Pharmacokinetics of Tiotropium Delivered From Test Inhaler Products With A Reference Product

FDA applications (4)

Application

Approved

Type

Applicant

Products

NDA 208288

2018-08-08

NDA

SOLVENTUM US LLC

NDA 021586

2006-09-29

NDA

SOLVENTUM US LLC

NDA 021074

2001-06-07

NDA

SOLVENTUM US LLC

NDA 019028

1986-08-13

NDA

SOLVENTUM US LLC